178 related articles for article (PubMed ID: 37751373)
1. Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging.
Abrahams T; Fujino M; Nelson AJ; Nicholls SJ
Curr Opin Cardiol; 2023 Nov; 38(6):504-508. PubMed ID: 37751373
[TBL] [Abstract][Full Text] [Related]
2. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
[TBL] [Abstract][Full Text] [Related]
3. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ
JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172
[TBL] [Abstract][Full Text] [Related]
4. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.
Räber L; Ueki Y; Otsuka T; Losdat S; Häner JD; Lonborg J; Fahrni G; Iglesias JF; van Geuns RJ; Ondracek AS; Radu Juul Jensen MD; Zanchin C; Stortecky S; Spirk D; Siontis GCM; Saleh L; Matter CM; Daemen J; Mach F; Heg D; Windecker S; Engstrøm T; Lang IM; Koskinas KC;
JAMA; 2022 May; 327(18):1771-1781. PubMed ID: 35368058
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy.
Biccirè FG; Häner J; Losdat S; Ueki Y; Shibutani H; Otsuka T; Kakizaki R; Hofbauer TM; van Geuns RJ; Stortecky S; Siontis GCM; Bär S; Lønborg J; Heg D; Kaiser C; Spirk D; Daemen J; Iglesias JF; Windecker S; Engstrøm T; Lang I; Koskinas KC; Räber L
J Am Coll Cardiol; 2023 Oct; 82(18):1737-1747. PubMed ID: 37640248
[TBL] [Abstract][Full Text] [Related]
6. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.
Rexhaj E; Bär S; Soria R; Ueki Y; Häner JD; Otsuka T; Kavaliauskaite R; Siontis GC; Stortecky S; Shibutani H; Spirk D; Engstrøm T; Lang I; Morf L; Ambühl M; Windecker S; Losdat S; Koskinas KC; Räber L;
Atherosclerosis; 2024 May; 392():117504. PubMed ID: 38513436
[TBL] [Abstract][Full Text] [Related]
7. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study.
Montarello NJ; Singh K; Sinhal A; Wong DTL; Alcock R; Rajendran S; Dautov R; Barlis P; Patel S; Nidorf SM; Thompson PL; Salagaras T; Butters J; Nerlekar N; Di Giovanni G; Ottaway JL; Nicholls SJ; Psaltis PJ
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1175-1186. PubMed ID: 34432196
[TBL] [Abstract][Full Text] [Related]
9. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.
Gao F; Wang ZJ; Ma XT; Shen H; Yang LX; Zhou YJ
Lipids Health Dis; 2021 Sep; 20(1):106. PubMed ID: 34511134
[TBL] [Abstract][Full Text] [Related]
10. Effect of Evolocumab on Coronary Plaque Composition.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Schwartz GG; Giugliano RP
Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
[TBL] [Abstract][Full Text] [Related]
12. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
13. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
14. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Liang D; Li C; Tu Y; Li Z; Zhang M
Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
16. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
17. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
Otake H; Sugizaki Y; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Kawamori H; Shinke T; Hirata KI
J Cardiol; 2019 Mar; 73(3):228-232. PubMed ID: 30579806
[TBL] [Abstract][Full Text] [Related]
19. Impact of statins on serial coronary calcification during atheroma progression and regression.
Puri R; Nicholls SJ; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nissen SE
J Am Coll Cardiol; 2015 Apr; 65(13):1273-1282. PubMed ID: 25835438
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study.
Ota H; Omori H; Kawasaki M; Hirakawa A; Matsuo H
Eur Heart J Cardiovasc Imaging; 2022 Jan; 23(2):217-228. PubMed ID: 33637979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
